European Commission approves nivolumab plus ipilimumab combination for first-line advanced RCC

The European Commission has approved the nivolumab plus ipilimumab combination for first-line treatment of people with intermediate- and poor-risk advanced renal cell carcinoma (RCC). This is the first approval of a combination of immunotherapy agents for untreated advance RCC in the European Union. This approval offers advanced RCC patients in Europe a first-line treatment with a […]

read more

Pros and cons of lymph node dissection at the time of nephrectomy

The following two presentations were given at the Canadian Uro-oncology Summit in Toronto last week on the pros and cons of removing lymph nodes during nephrectomy for renal cell carcinoma (RCC). In summary, lymph node dissection may be curative in patients with non-metastatic RCC, and may improve the patient’s response to systemic treatment in patients […]

read more

Biopsy of small renal masses – still controversial?

Dr Finelli from the Princess Margaret Cancer Centre in Toronto, Canada, gave a presentation in favour of the biopsy of small renal masses at the Canadian Uro-oncology Summit in Toronto last week. In summary, a renal tumour biopsy is accurate, safe, impacts management, avoids over-treatment and enables personalised care for each patient. Dr Finelli recommends […]

read more

Real world evidence as a complement to clinical trials

The review article highlights the usefulness of real world evidence to add substantially to the information available to the scientific and medical communities. Randomised clinical trials have traditionally been the gold-standard for scientific evidence. However, randomised clinical trials are not able to answer all the questions necessary for clinical decision-making. Real world evidence refers to […]

read more

Personalised vaccine to be tested in patients with kidney cancer

Scientists at the Dana-Farber Cancer Institute in Boston, USA, are testing a new personalised cancer vaccine, called NeoVax, for the treatment of kidney cancer patients at high risk of recurrence following surgery. The vaccine incorporates proteins (neoantigens) that are specific to the cancer cells in each individual’s tumour. The vaccine is then linked to a […]

read more

NHS Long Term Plan launched today

The new NHS Long Term Plan is published today with the aim to save almost half a million more lives through investment in innovative, high-end treatments and a focus on major life-threatening conditions, such as heart disease and cancer. An extra £20 billion is to go to the NHS, and GPs, mental health and community […]

read more

Breath test for cancer enters clinical trials

Cancer Research UK are pioneering a potential breath test for cancer. A clinical trial, being led by Professor Rebecca Fitzgerald, is about to start at the MRC Cancer Unit at the University of Cambridge. The trial is looking at ways to bring this potential cancer test into the clinic. “The PAN trial is seeing if you […]

read more

Prognosis of kidney cancer patients with bone metastases

A recent study published in the European Journal of Cancer this month suggests that the Memorial Sloan-Kettering Cancer Center (MSKCC) risk score, the number of bone metastases, and surgical removal of bone metastases (radical resection) are important prognostic factors for patients with bone metastases from renal cell carcinoma (RCC). In addition, surgery to remove solitary […]

read more

Kidney stones associated with an increased risk of kidney cancer

A recent study involving 5,000 patients from The Netherlands who were followed for 2 decades suggests when kidney stones are diagnosed at an early age (less than 40 years old) they were significantly associated with an overall increase in risk of developing renal cell carcinoma (RCC) compared to when kidney stones are diagnosed later in […]

read more

Current role of mTOR inhibitors in metastatic kidney cancer

The following video interview with Dr Eric Jonasch, from the MD Anderson Cancer Center, Houston, Texas, describes the current role of mTOR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC). Watch the video interview on Practice Update here

read more
Showing 1 to 10 of 431 results
  TOP